Spero Therapeutics (NASDAQ:SPRO) Shares Pass Above 200 Day Moving Average - What's Next?

Spero Therapeutics, Inc. (NASDAQ:SPRO - Get Free Report) shares crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.03 and traded as high as $2.98. Spero Therapeutics shares last traded at $2.94, with a volume of 1,836,464 shares traded.

Spero Therapeutics Stock Up 1.4%

The stock has a market cap of $164.38 million, a P/E ratio of -2.30 and a beta of 1.31. The stock has a fifty day simple moving average of $1.32 and a 200-day simple moving average of $1.03.

Spero Therapeutics (NASDAQ:SPRO - Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.55) by $0.30. Spero Therapeutics had a negative return on equity of 123.50% and a negative net margin of 156.48%. The firm had revenue of $5.87 million for the quarter, compared to analysts' expectations of $11.00 million. Sell-side analysts anticipate that Spero Therapeutics, Inc. will post -1.2 earnings per share for the current year.

Hedge Funds Weigh In On Spero Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SPRO. Three Seasons Wealth LLC acquired a new stake in shares of Spero Therapeutics during the fourth quarter worth about $31,000. XTX Topco Ltd acquired a new stake in shares of Spero Therapeutics during the fourth quarter worth about $31,000. Virtu Financial LLC acquired a new stake in shares of Spero Therapeutics during the fourth quarter worth about $47,000. Prudential Financial Inc. acquired a new stake in shares of Spero Therapeutics during the fourth quarter worth about $51,000. Finally, Jane Street Group LLC acquired a new stake in shares of Spero Therapeutics during the fourth quarter worth about $54,000. Institutional investors own 25.60% of the company's stock.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.